Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2009 2
2011 4
2012 15
2013 12
2014 11
2015 27
2016 65
2017 64
2018 55
2019 34
2020 67
2021 14
Text availability
Article attribute
Article type
Publication date

Search Results

321 results
Results by year
Filters applied: . Clear all
Page 1
Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma.
Dimopoulos MA, Dytfeld D, Grosicki S, Moreau P, Takezako N, Hori M, Leleu X, LeBlanc R, Suzuki K, Raab MS, Richardson PG, Popa McKiver M, Jou YM, Shelat SG, Robbins M, Rafferty B, San-Miguel J. Dimopoulos MA, et al. N Engl J Med. 2018 Nov 8;379(19):1811-1822. doi: 10.1056/NEJMoa1805762. N Engl J Med. 2018. PMID: 30403938 Clinical Trial.
METHODS: Patients with multiple myeloma that was refractory or relapsed and refractory to lenalidomide and a proteasome inhibitor were randomly assigned to receive elotuzumab plus pomalidomide and dexamethasone (elotuzumab group) or pomalidomide and dexamethasone al …
METHODS: Patients with multiple myeloma that was refractory or relapsed and refractory to lenalidomide and a proteasome inhibitor were rando …
Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma.
Lonial S, Dimopoulos M, Palumbo A, White D, Grosicki S, Spicka I, Walter-Croneck A, Moreau P, Mateos MV, Magen H, Belch A, Reece D, Beksac M, Spencer A, Oakervee H, Orlowski RZ, Taniwaki M, Röllig C, Einsele H, Wu KL, Singhal A, San-Miguel J, Matsumoto M, Katz J, Bleickardt E, Poulart V, Anderson KC, Richardson P; ELOQUENT-2 Investigators. Lonial S, et al. N Engl J Med. 2015 Aug 13;373(7):621-31. doi: 10.1056/NEJMoa1505654. Epub 2015 Jun 2. N Engl J Med. 2015. PMID: 26035255 Free article. Clinical Trial.
METHODS: In this phase 3 study, we randomly assigned patients to receive either elotuzumab plus lenalidomide and dexamethasone (elotuzumab group) or lenalidomide and dexamethasone alone (control group). ...Median progression-free survival in the elotuzumab gr …
METHODS: In this phase 3 study, we randomly assigned patients to receive either elotuzumab plus lenalidomide and dexamethasone (el
The Clinical Pharmacology of Elotuzumab.
Passey C, Sheng J, Mora J, Tendolkar A, Robbins M, Dodge R, Roy A, Bello A, Gupta M. Passey C, et al. Clin Pharmacokinet. 2018 Mar;57(3):297-313. doi: 10.1007/s40262-017-0585-6. Clin Pharmacokinet. 2018. PMID: 28779463 Review.
Elotuzumab antidrug antibodies occurred in 18.5% of patients treated with ELd or elotuzumab plus bortezomib and dexamethasone, but were generally transient and did not affect elotuzumab efficacy or safety. A monotherapy study indicated elotuzumab does
Elotuzumab antidrug antibodies occurred in 18.5% of patients treated with ELd or elotuzumab plus bortezomib and dexamethasone,
Mechanisms of NK Cell Activation and Clinical Activity of the Therapeutic SLAMF7 Antibody, Elotuzumab in Multiple Myeloma.
Campbell KS, Cohen AD, Pazina T. Campbell KS, et al. Front Immunol. 2018 Nov 5;9:2551. doi: 10.3389/fimmu.2018.02551. eCollection 2018. Front Immunol. 2018. PMID: 30455698 Free PMC article. Review.
Elotuzumab can stimulate robust antibody-dependent cellular cytotoxicity (ADCC) through engaging with FcgammaRIIIA (CD16) on NK cells and antibody-dependent cellular phagocytosis (ADCP) by macrophages. ...We review the current understanding of how elotuzumab utilize
Elotuzumab can stimulate robust antibody-dependent cellular cytotoxicity (ADCC) through engaging with FcgammaRIIIA (CD16) on NK cells
Elotuzumab in combination with pomalidomide and dexamethasone for the treatment of multiple myeloma.
Eleutherakis-Papaiakovou E, Gavriatopoulou M, Ntanasis-Stathopoulos I, Kastritis E, Terpos E, Dimopoulos MA. Eleutherakis-Papaiakovou E, et al. Expert Rev Anticancer Ther. 2019 Nov;19(11):921-928. doi: 10.1080/14737140.2019.1685879. Epub 2019 Nov 4. Expert Rev Anticancer Ther. 2019. PMID: 31679403 Review.
Several combinations of monoclonal antibodies with novel agents are being investigated with promising results in order to prolong progression-free and overall survival.Areas covered: This paper aims to critically present available data from clinical trials investigating the combi …
Several combinations of monoclonal antibodies with novel agents are being investigated with promising results in order to prolong progressio …
Elotuzumab: A Review in Relapsed and/or Refractory Multiple Myeloma.
Lamb YN. Lamb YN. Drugs. 2018 Sep;78(14):1481-1488. doi: 10.1007/s40265-018-0969-4. Drugs. 2018. PMID: 30232695 Review.
The clinical benefit of elotuzumab was maintained over the longer term ( 4 years' minimum follow-up); final overall survival data are awaited. Health-related quality of life was not negatively impacted by the addition of elotuzumab. Elotuzumab combination the …
The clinical benefit of elotuzumab was maintained over the longer term ( 4 years' minimum follow-up); final overall survival data are …
Elotuzumab as a novel anti-myeloma immunotherapy.
Radhakrishnan SV, Bhardwaj N, Steinbach M, Weidner J, Luetkens T, Atanackovic D. Radhakrishnan SV, et al. Hum Vaccin Immunother. 2017 Aug 3;13(8):1751-1757. doi: 10.1080/21645515.2017.1327487. Epub 2017 Jun 12. Hum Vaccin Immunother. 2017. PMID: 28604269 Free PMC article. Review.
Although preclinical data looked very promising, elotuzumab monotherapy did not result in objective clinical responses in patients with relapsed/refractory multiple myeloma. ...Currently, there are several clinical trials ongoing investigating the role of elotuzumab
Although preclinical data looked very promising, elotuzumab monotherapy did not result in objective clinical responses in patients wi …
Elotuzumab.
[No authors listed] [No authors listed] 2017 Mar 25. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. 2012–. PMID: 31644037 Free Books & Documents. Review.
Elotuzumab is a humanized monoclonal antibody to cell surface receptor SLAMF7 which is used in combination with other antineoplastic agents in the therapy of multiple myeloma. Elotuzumab has been implicated in rare instances of transient, marked serum enzyme elevati
Elotuzumab is a humanized monoclonal antibody to cell surface receptor SLAMF7 which is used in combination with other antineoplastic
The role of elotuzumab in the treatment of relapsed or refractory multiple myeloma.
Comeau JM, Kelly K, Jean GW. Comeau JM, et al. Am J Health Syst Pharm. 2018 Jan 15;75(2):55-66. doi: 10.2146/ajhp160554. Am J Health Syst Pharm. 2018. PMID: 29317395 Review.
Elotuzumab plus bortezomib and dexamethasone is an NCCN-recommended alternative option for relapsed or refractory MM. ...Key factors in patient selection for elotuzumab therapy include adverse effects, prior treatments received, and cost considerations....
Elotuzumab plus bortezomib and dexamethasone is an NCCN-recommended alternative option for relapsed or refractory MM. ...Key factors
Elotuzumab.
[No authors listed] [No authors listed] 2020 Sep 21. Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006–. Drugs and Lactation Database (LactMed). 2006–. PMID: 29999843 Free Books & Documents. Review.
No information is available on the clinical use of elotuzumab during breastfeeding. Because elotuzumab is a large protein molecule with a molecular weight of 148,100 Da, the amount in milk is likely to be very low and absorption is unlikely because it is probably de …
No information is available on the clinical use of elotuzumab during breastfeeding. Because elotuzumab is a large protein mole …
321 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page